Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

3.560 -0.200 (-5.32%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	20,808,273
Open	3.800
Bid (Size)	3.560 (200)
Ask (Size)	3.570 (600)
Prev. Close	3.760
Today's Range	3.440 - 3.800
52wk Range	2.770 - 7.180
Shares Outstanding	168,425,907
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

July 05, 2026

Two stocks that have fallen out of favor and one hot stock that was one of Thursday's biggest losers were on the Ark Invest founder's shopping list.

Via The Motley Fool

Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026? ↗

July 04, 2026

Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, and industry partnerships.

Via The Motley Fool

Performance

YTD	-15.2%	-15.2%
1 Month	+17.1%	+17.1%
3 Month	+8.5%	+8.5%
6 Month	-23.6%	-23.6%
1 Year	-37.7%	-37.7%

More News

Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026? ↗

July 03, 2026

Via The Motley Fool

Recursion Pharmaceuticals (RXRX) Q1 2026 Results: Revenue Miss Overshadows Narrower Net Loss ↗

May 06, 2026

Via Chartmill

Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗

June 30, 2026

Via The Motley Fool

Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion Market ↗

June 27, 2026

Via The Motley Fool

2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider Buying ↗

June 26, 2026

Via The Motley Fool

Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026? ↗

June 02, 2026

Via The Motley Fool

Recursion to Participate in Upcoming Investor Conferences

June 02, 2026

From Recursion Pharmaceuticals

Via GlobeNewswire

Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

May 29, 2026

From Recursion Pharmaceuticals

Via GlobeNewswire

Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now? ↗

May 25, 2026

Via The Motley Fool

A Deep Dive Into NVIDIA’s Latest Portfolio Moves ↗

May 19, 2026

Via MarketBeat

TechMediaBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Advances AI Voice-Based Intoxication Detection as Real-Time Diagnostics Market Expands

May 11, 2026

Via Investor Brand Network

The Future of Intoxication Detection May Be in Your Voice

May 11, 2026

Via Investor Brand Network

The Future of Intoxication Detection May Be in Your Voice

May 11, 2026

From BioMedWire

Via GlobeNewswire

3 Stocks Poised to Disrupt the Healthcare Market by 2030 ↗

May 08, 2026

Via The Motley Fool

Recursion (RXRX) Q1 2026 Earnings Transcript ↗

May 07, 2026

Via The Motley Fool

Recursion Reports First Quarter Financial Results and Provides Business Update

May 06, 2026

From Recursion Pharmaceuticals

Via GlobeNewswire

Recursion Announces Board Transition

April 30, 2026

From Recursion Pharmaceuticals

Via GlobeNewswire

Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6

April 29, 2026

From Recursion Pharmaceuticals

Via GlobeNewswire

Recursion to Participate in Upcoming Investor Conferences

April 07, 2026

From Recursion Pharmaceuticals

Via GlobeNewswire

Lilly’s $47.8 Billion Bet: Why the Contessa Acquisition Redefines the Future of Medicine

April 06, 2026

Via MarketMinute

1 Beaten-Down AI Stock to Buy and 1 to Avoid ↗

April 01, 2026

Via The Motley Fool

Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform

March 31, 2026

From Citeline

Via GlobeNewswire

2 AI Healthcare Stocks to Buy Right Now ↗

March 31, 2026

Via The Motley Fool

Frequently Asked Questions

Is Recursion Pharmaceuticals, Inc. - Class A Common Stock publicly traded?

Yes, Recursion Pharmaceuticals, Inc. - Class A Common Stock is publicly traded.

What exchange does Recursion Pharmaceuticals, Inc. - Class A Common Stock trade on?

Recursion Pharmaceuticals, Inc. - Class A Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock?

The ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock is RXRX on the Nasdaq Stock Market

What is the current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock?

The current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 3.560

When was Recursion Pharmaceuticals, Inc. - Class A Common Stock last traded?

The last trade of Recursion Pharmaceuticals, Inc. - Class A Common Stock was at 07/10/26 04:00 PM ET

What is the market capitalization of Recursion Pharmaceuticals, Inc. - Class A Common Stock?

The market capitalization of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 599.60M

How many shares of Recursion Pharmaceuticals, Inc. - Class A Common Stock are outstanding?

Recursion Pharmaceuticals, Inc. - Class A Common Stock has 600M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.